Latest news with #Miltenyi
Time of India
12 hours ago
- Business
- Time of India
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy
HYDERABAD: In a move aimed at beefing up India's leadership in cutting-edge biotherapeutics such as cell and gene therapy (CGT), the Biotechnology Industry Research Assistance Council (BIRAC) has signed a strategic letter of intent (LOI) with Miltenyi Biotec India Private Limited to boost India's capabilities in CGT through capacity building, advancing clinical research and solving unmet medical needs by local manufacturing of cell therapies. The LOI was signed at the BIO International Convention 2025 that kicked off in Boston this week. Through the partnership, Miltenyi Biotec and BIRAC plan to build national capabilities and upskill scientific talent through structured training and capacity-building programmes for clinicians, researchers, and technicians in CGT manufacturing, analytics, and quality control. The collaboration also aims to expand translational research efforts through co-development of academic and multi-center studies, focusing on next-generation therapies to solve India's unmet medical needs in malignancies, autoimmune diseases and rare diseases. It will also establish point-of-care (PoC) CAR-T centers across India using automated manufacturing platforms such as Miltenyi's CliniMACS Prodigy system to enable cost-effective and scalable access to personalised CGT treatments. The initiative will also promote targeted cell therapy research and support local innovation through the identification and mentoring of Indian startups in line with the 'Make in India' mission by enhancing domestic production of critical and manufacturing components, and supporting the development of national CGT centers of excellence. Commenting on the partnership. Priya Kapoor-Hingorani, managing director, MiltenyiBiotec India, said, 'The potential of India draws us. Our partnership with BIRAC focuses on updating and upskilling scientists to strengthen the country's scientific capabilities and infrastructure. Together, we're exploring how to address current unmet needs in medical science, particularly in areas like autoimmune and rare diseases by enhancing access through innovative mechanisms such as point-of-care CAR-T and graft engineering. ' BIRAC managing director Dr Jitendra Kumar said the LOI was inked with Miltenyi, an MNC that is known for its expertise in CGT, as India is aspiring to become a global leader in this space and to achieve that goal it requires a strong foundation of skilled manpower.
Yahoo
31-05-2025
- Business
- Yahoo
Bio-Techne Corporation (TECH): A Bull Case Theory
We came across a bullish thesis on Bio-Techne Corporation (TECH) on scuttleblurb's Substack. In this article, we will summarize the bulls' thesis on TECH. Bio-Techne Corporation (TECH)'s share was trading at $47.93 as of 28th May. TECH's trailing and forward P/E were 57.75 and 22.03 respectively according to Yahoo Finance. A close-up of a biotechnology machine working on an oncology therapy. Bio-Techne has built a diverse and complex business centered on its strong legacy in recombinant proteins, expanding downstream into antibodies, assays, and instrument platforms, while also moving into cell and gene therapy (CGT) solutions. Its revenue is split roughly between Protein Sciences and Diagnostics, which are closely linked—diagnostics identify disease biomarkers that then become therapeutic targets developed using Bio-Techne's proteins and antibodies. Despite about 20 acquisitions over the past decade, its core legacy products still contribute 56% of total revenue, with the remainder coming from faster-growing, less penetrated markets. Around half of Bio-Techne's revenue comes from commercial R&D, now dominated by smaller, venture-funded biotechs rather than big pharma, making this segment more cyclical. Academia accounts for another 20%, a price-sensitive group vulnerable to budget swings. The company is gaining ground in GMP protein production for clinical and commercial use, a highly regulated and lucrative niche, though it trails established leaders like Miltenyi and Cellgenix. Bio-Techne has also expanded into proteomics and spatial biology through acquisitions. While the company once forecasted nearly $2 billion in revenue by 2026, growth slowed due to several factors: COVID-related demand spikes followed by inventory destocking, a 20-30% revenue decline in China, fading COVID testing tailwinds, and cautious FDA oversight of CGTs that hurt growth expectations. Despite these setbacks causing a nearly 50% stock price decline, recent signs point to recovery with organic growth rebounding to 9% and instrument sales improving. Bio-Techne's broad strategy reflects its efforts to protect core franchises while expanding into new growth areas, including becoming an instrument provider to capture more downstream value. Bio-Techne Corporation (TECH) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 34 hedge fund portfolios held TECH at the end of the first quarter which was 24 in the previous quarter. While we acknowledge the risk and potential of TECH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than TECH but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
